Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization

Background: We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fert...

Full description

Bibliographic Details
Main Authors: Ayse Figen Turkcapar, Berna Seckin, Gogsen Onalan, Tulin Ozdener, Sertac Batioglu
Format: Article
Language:English
Published: Royan Institute (ACECR), Tehran 2013-01-01
Series:International Journal of Fertility and Sterility
Subjects:
hmg
Online Access:http://www.ijfs.ir/article_45152_efb0ee8a85dcd7933348f4a4d2ebc63e.pdf
id doaj-8ca13b18b65f46c5b7e51ab48dffb2d1
record_format Article
spelling doaj-8ca13b18b65f46c5b7e51ab48dffb2d12020-11-25T04:05:26ZengRoyan Institute (ACECR), TehranInternational Journal of Fertility and Sterility2008-076X2008-07782013-01-016423824345152Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro FertilizationAyse Figen Turkcapar0Berna Seckin1Gogsen Onalan2Tulin Ozdener3Sertac Batioglu4Department of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyDepartment of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, TurkeyDepartment of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyBackground: We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fertilization (IVF). Materials and Methods: This prospective randomized controlled trial included a total of 80 women with PCOS. Of these, 38 were randomized to receive treatment with hMG and 42 with rFSH using a long gonadotropin releasing hormone (GnRH) analogue protocol. Outcome measures were cycle characteristics, pregnancy rates, the need for coasting, and OHSS rates. Results: In the hMG group we observed a significantly lower peak estradiol (E2) level (p=0.02), fewer intermediate-sized follicles (p=0.001), lower number of oocytes retrieved (p=0.002) and metaphase II (MII) oocytes (p=0.003). However, there were no significant differences between the groups in the number of fertilized oocytes, fertilization rates, top quality embryo counts, and the number of transferred embryos. There was no difference in pregnancy rates between the groups. OHSS occurred in 11.9% of the rFSH group patients, whereas no OHSS developed in the hMG group. Coasting requirements were lower in the hMG group (19.2% vs. 48.9%, p=0.013). Conclusion: Ovarian stimulation with hMG and rFSH provides similar clinical pregnancy rates in PCOS patients treated with a long GnRH agonist protocol in IVF cycles. hMG stimulation appears to be associated with a lower rate of OHSS and decreased coasting requirements (Registration Number: NCT01365936).http://www.ijfs.ir/article_45152_efb0ee8a85dcd7933348f4a4d2ebc63e.pdfhmgrecombinant fshfertilizationpolycystic ovary syndrome
collection DOAJ
language English
format Article
sources DOAJ
author Ayse Figen Turkcapar
Berna Seckin
Gogsen Onalan
Tulin Ozdener
Sertac Batioglu
spellingShingle Ayse Figen Turkcapar
Berna Seckin
Gogsen Onalan
Tulin Ozdener
Sertac Batioglu
Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
International Journal of Fertility and Sterility
hmg
recombinant fsh
fertilization
polycystic ovary syndrome
author_facet Ayse Figen Turkcapar
Berna Seckin
Gogsen Onalan
Tulin Ozdener
Sertac Batioglu
author_sort Ayse Figen Turkcapar
title Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
title_short Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
title_full Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
title_fullStr Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
title_full_unstemmed Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
title_sort human menopausal gonadotropin versus recombinant fsh in polycystic ovary syndrome patients undergoing in vitro fertilization
publisher Royan Institute (ACECR), Tehran
series International Journal of Fertility and Sterility
issn 2008-076X
2008-0778
publishDate 2013-01-01
description Background: We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fertilization (IVF). Materials and Methods: This prospective randomized controlled trial included a total of 80 women with PCOS. Of these, 38 were randomized to receive treatment with hMG and 42 with rFSH using a long gonadotropin releasing hormone (GnRH) analogue protocol. Outcome measures were cycle characteristics, pregnancy rates, the need for coasting, and OHSS rates. Results: In the hMG group we observed a significantly lower peak estradiol (E2) level (p=0.02), fewer intermediate-sized follicles (p=0.001), lower number of oocytes retrieved (p=0.002) and metaphase II (MII) oocytes (p=0.003). However, there were no significant differences between the groups in the number of fertilized oocytes, fertilization rates, top quality embryo counts, and the number of transferred embryos. There was no difference in pregnancy rates between the groups. OHSS occurred in 11.9% of the rFSH group patients, whereas no OHSS developed in the hMG group. Coasting requirements were lower in the hMG group (19.2% vs. 48.9%, p=0.013). Conclusion: Ovarian stimulation with hMG and rFSH provides similar clinical pregnancy rates in PCOS patients treated with a long GnRH agonist protocol in IVF cycles. hMG stimulation appears to be associated with a lower rate of OHSS and decreased coasting requirements (Registration Number: NCT01365936).
topic hmg
recombinant fsh
fertilization
polycystic ovary syndrome
url http://www.ijfs.ir/article_45152_efb0ee8a85dcd7933348f4a4d2ebc63e.pdf
work_keys_str_mv AT aysefigenturkcapar humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization
AT bernaseckin humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization
AT gogsenonalan humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization
AT tulinozdener humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization
AT sertacbatioglu humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization
_version_ 1724433951433424896